Abstract
ObjectiveThe prognostic significance of CD147 expression in esophageal cancer patients remains controversial. Using a meta-analysis, we investigated the prognostic and clinicopathologic characteristics of CD147 in esophageal cancer.MethodsA comprehensive literature search of the PubMed (1966–2016), EMBASE (1980–2016), Cochrane Library (1996–2016), Web of Science (1945–2016), China National Knowledge Infrastructure (1982–2016), and Wanfang databases (1988–2016) was performed to identify studies of all esophageal cancer subtypes. Correlations between CD147 expression and survival outcomes and clinicopathological features were analyzed using meta-analysis methods.ResultsSeventeen studies were included. High CD147 expression reduced the 3-year survival rate (OR = 3.26, 95% CI = (1.53, 6.93), p = 0.02) and 5-year survival rate(OR = 4.35, 95% CI = (2.13, 8.90), p < 0.0001). High CD147 expression reduced overall survival in esophageal cancer (HR = 1.60, 95% CI = (1.19, 2.15), p = 0.02). Additionally, higher CD147 expression was detected in esophageal cancer tissues than noncancerous tissues (OR = 9.45, 95% CI = (5.39, 16.59), p < 0.00001), normal tissues (OR = 12.73, 95% CI = (3.49, 46.46), p = 0.0001), para-carcinoma tissues (OR = 12.80, 95% CI = (6.57, 24.92), p < 0.00001), and hyperplastic tissues (OR = 3.27, 95% CI = (1.47, 7.29), p = 0.004). CD147 expression was associated with TNM stage (OR = 3.66, 95% CI = (2.20, 6.09), p < 0.00001), tumor depth (OR = 7.97, 95% CI = (4.13, 15.38), p < 0.00001), and lymph node status (OR = 5.14, 95% CI = (2.03,13.01), p = 0.0005), but not with tumor differentiation, age, or sex.ConclusionOur meta-analysis suggests that CD147 is an efficient prognostic factor in esophageal cancer. High CD147 expression in patients with esophageal cancer was associated with worse survival outcomes and common clinicopathological indicators of poor prognosis.
Highlights
Esophagus cancer (EC) is a malignant disease with the eighth incidence rate and the sixth mortality rate wordwide[1, 2]
High CD147 expression reduced overall survival in esophageal cancer (HR = 1.60, 95% confidence intervals (95% CI) = (1.19, 2.15), p = 0.02)
Higher CD147 expression was detected in esophageal cancer tissues than noncancerous tissues (OR = 9.45, 95% CI = (5.39, 16.59), p < 0.00001), normal tissues (OR = 12.73, 95% CI = (3.49, 46.46), p = 0.0001), para-carcinoma tissues (OR = 12.80, 95% CI = (6.57, 24.92), p < 0.00001), and hyperplastic tissues (OR = 3.27, 95% CI = (1.47, 7.29), p = 0.004)
Summary
Esophagus cancer (EC) is a malignant disease with the eighth incidence rate and the sixth mortality rate wordwide[1, 2]. The prognosis of EC is unfavorable, largely due to its unapparent symptom at the early stage and tumor infiltration and metastasis which makes it hard to completely remove the tumor by surgery[3]. It is with great significance to study the molecular mechanism in the development, invasion and metastasis of EC. It is proved that the expression of some molecules, such as NF-kappaB, MIF, CXCR4 and EGFR, are related to the treatment or the prognosis of EC[4–6]. CD147, named extracellular matrix (ECM) metalloproteinase inducer, is a molecule highly expressed on the surface of cancer cells and promotes the secretion of matrix metalloproteinases (MMPs) from fibroblasts, degrading the matrix of cancer cell and facilitating the invasion and metastasis of cancer[7, 8]. Numerous papers showed that CD147 plays an important role in different sorts of cancer, including bladder cancer, prostate cancer, ovarian cancer, glioma, and esophageal cancer is one of them[9–14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
